OsteoSys Co., Ltd.
• Prolonged immobilization
• Conditions associated with secondary osteoporosis, such as
gastrointestinal malabsorption or malnutrition, sprue, osteomalacia,
vitamin D deficiency, endometriosis, acromegaly, chronic alcoholism or
established cirrhosis, and multiple myeloma
• Individuals who have had a gastric bypass for obesity
Individuals considering pharmacologic therapy for osteoporosis.
Individuals monitored for:
• Assess the effectiveness of osteoporosis drug therapy
• Follow-up medical conditions associated with abnormal BMD.
Children or adolescents with medical conditions associated with abnormal
BMD including but not limited to:
• Individuals receiving (or expected to receive) glucocorticoid therapy for
more than 3 months
• Individuals receiving radiation or chemotherapy for malignancies
• Individuals with an endocrine disorder known to adversely affect BMD
(e.g., hyperparathyroidism, hyperthyroidism, growth hormone deficiency or
Cushing’s syndrome)
• Individuals with bone dysplasia known to have excessive fracture risk
(osteogenesis imperfecta, osteopetrosis) or high bone density
• Individuals with medical conditions that could change BMD, for example:
1. Chronic renal failure
2. Rheumatoid arthritis and other inflammatory arthritis
3. Eating disorders, including anorexia nervosa and bulimia
4. Organ transplantation
5. Prolonged immobilization
6. Conditions associated with secondary osteoporosis, such as;
gastrointestinal malabsorption, sprue, inflammatory bowel disease,
malnutrition, osteomalacia, vitamin D deficiency, acromegaly, cirrhosis, HIV
infection, prolonged exposure to fluorides
QUS may be indicated in the diagnosis, staging, and follow-up of individuals
with conditions that result in pathologically increased BMD, such as
osteopetrosis or prolonged exposure to fluoride.
To Next Page
Loading...
